FETUIN A IN HEPATITIS C PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS
Mona Sayed Mohamed El-Sayed Zaky;
Abstract
SUMMARY
Background:
F
etuin-A is a 60 kDa glycoprotein produced exclusively by the liver and secreted into serum in relatively high con-centrations in humans. Fetuin-A is known to inhibit ectopic calcium deposition and protect from vascular calcification.3 The low fetuin-A level may be associated with higher cardiovascular mortality in liver cirrhosis and cancer and also in chronic renal failure patients on long term dialysis. Also, fetuin-A is shown to act as an endogeneous inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle, resulting in IR in these target tissues.
Aim of the work:
This study was conducted to correlate between fetuin-A and chronic hepatitis C virus infection, and also insulin resistance in patients with type 2 diabetes mellitus. Other correlations between fetuin-A level and different laboratory parameters were assessed.
80 subjects were enrolled in this study. They were divided into three groups; 20 control normal individuals as group I, 30 hepatitis C positive patients with diabetes as group II and 30 hepatitis C positive patients without diabetes as group III.
The present study demonstrates that:
There was a statistically highly significant difference as regard Fetuin-A, as p-value is less than 0.001, being higher in group II and III than group I.
There was a highly significant positive correlation between fetuin A and BMI where r=0.602 and p-value<0.001 also there is a significant positive correlation with fasting insulin where r=0.278 and P-value=0.031 and with Homa IR where r=0.377 and P-value=0.025.
Background:
F
etuin-A is a 60 kDa glycoprotein produced exclusively by the liver and secreted into serum in relatively high con-centrations in humans. Fetuin-A is known to inhibit ectopic calcium deposition and protect from vascular calcification.3 The low fetuin-A level may be associated with higher cardiovascular mortality in liver cirrhosis and cancer and also in chronic renal failure patients on long term dialysis. Also, fetuin-A is shown to act as an endogeneous inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle, resulting in IR in these target tissues.
Aim of the work:
This study was conducted to correlate between fetuin-A and chronic hepatitis C virus infection, and also insulin resistance in patients with type 2 diabetes mellitus. Other correlations between fetuin-A level and different laboratory parameters were assessed.
80 subjects were enrolled in this study. They were divided into three groups; 20 control normal individuals as group I, 30 hepatitis C positive patients with diabetes as group II and 30 hepatitis C positive patients without diabetes as group III.
The present study demonstrates that:
There was a statistically highly significant difference as regard Fetuin-A, as p-value is less than 0.001, being higher in group II and III than group I.
There was a highly significant positive correlation between fetuin A and BMI where r=0.602 and p-value<0.001 also there is a significant positive correlation with fasting insulin where r=0.278 and P-value=0.031 and with Homa IR where r=0.377 and P-value=0.025.
Other data
| Title | FETUIN A IN HEPATITIS C PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS | Other Titles | فتوين أ في مرضى الالتهاب الكبدي الفيروسي سي مع أو بدون داء السكري من النوع الثاني | Authors | Mona Sayed Mohamed El-Sayed Zaky | Issue Date | 2015 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.